Author

G. M. Duarte

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access 2026

Prognostic impact of residual ductal carcinoma in situ following neoadjuvant chemotherapy for invasive breast cancer: a systematic review and meta-analysis

Introduction: Despite the definition of pathologic complete response (pCR) in the 8th edition of the AJCC Cancer Staging Manual as the absence of residual invasive disease after neoadjuvant chemotherapy (NAC), the prognostic significance of residual ductal carcinoma in situ (DCIS) remains uncertain. Objective: To asse...

Augusto Ostermann Magalhães, Maria Beatriz de Paula Leite Kraft, R. Torresan et al. · Mastology · 0 citations

Open access 2026

Survival implications of non-organized breast cancer screening in a brazilian tertiary women’s health center: a retrospective cohort study of 1,517 patients

Introduction/Justification: Breast cancer is the most common malignancy among Brazilian women, and advanced-stage diagnosis remains frequent, partly due to limited access to organized screening and timely treatment. Although screening is nationally recommended, implementation is largely opportunistic, and its prognosti...

N. Almeida, N. S. de Azevedo, F. Brenelli et al. · Mastology · 0 citations

Open access 2026

Oncological safety of sentinel lymph node biopsy with single mapping tracer in cN+/ypN0 breast cancer women post-neoadjuvant chemotherapy: a real-world data study

Introduction: Sentinel lymph node biopsy (SLNB) safety after neoadjuvant therapy in initially node-positive (cN+) breast cancer remains controversial. Additionally, evidence regarding the use of a single mapping tracer in this setting is limited. Methods: Women with non-metastatic cT1–3 cN0–cN2 breast cancer who were...

M. B. Kraft, Arthur Chaves de Almeida, F. Brenelli et al. · Mastology · 0 citations

Open access 2026

Economic impact of omitting sentinel lymph node biopsy in early breast cancer: a secondary analysis of the randomized venus trial

Introduction: The omission of sentinel lymph node biopsy (SLNB) in early breast cancer patients who are clinically node-negative has been explored. However, data regarding the economic implications of this strategy remain limited. The VENUS trial is designed to evaluate SLNB omission. Objective: This report presents a...

A. S. Detoni, G. M. Duarte, D. Araújo et al. · Mastology · 0 citations